• Inconclusive results from MOA studies on Anti-Obesity Project
• Planning limited pharmacokinetic multidose Phase 1 study on compound AOC
• Continuing business development discussions and reviewing opportunities

Anatara Lifesciences Ltd (ASX: ANR) has provided a Quarterly Activities/Appendix 4C Cash Flow Report for the quarter ending March 2026. The key highlights include:- The company announced that the Mechanism of Action (MOA) assays were completed on the pre-clinical studies of the Anti-Obesity Project, with the results being equivocal in providing evidence of a direct rise in endogenous GLP-1 in response to dosing with the candidate compound AOC.- The company is planning a limited pharmacokinetic multidose Phase 1 Study to evaluate compound AOC, with the design for such a clinical study on compound AOC, with healthy human volunteers, sent for tender in Australia and the EU.- The company's activities continue as previously outlined, including business development discussions to pursue further opportunities including M&A.- Cash at the end of the March Quarter was $0.707 million, and the company continues to maintain prudent financial control over operations.- The summation of the GaRP Project pre-clinical and clinical work for publication were progressed, and there remains commercial interest in the GaRP Project IP.